Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CLEOPATTRA in transthyretin amyloid cardiomyopathy
jRCT2071250120Recruiting
- Sponsor
- Novo Nordisk
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial in amyloidotic transthyretin cardiomyopathy (ATTR-CM) comparing NNC6019-0001 with Placebo (2 arms). Primary endpoint: Number of occurrences of composite endpoint of cardiovascular deaths and recurrent cardiovascular events. Started Jan 2026; status: recruiting.
02
Drugs
coramitug
03
Conditions
amyloidotic transthyretin cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on jRCT2071250120.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2071250120.